Targeted sequencing analysis of hyper-eosinophilic syndrome and chronic eosinophilic leukemia
10.3760/cma.j.issn.0253-2727.2018.06.013
- VernacularTitle: 高嗜酸性粒细胞综合征及慢性嗜酸性粒细胞白血病的靶向测序研究
- Author:
Shiqiang QU
1
;
Tiejun QIN
;
Zefeng XU
;
Yue ZHANG
;
Yujiao JIA
;
Xiaofei AI
;
Hongli ZHANG
;
Liwei FANG
;
Naibo HU
;
Lijuan PAN
;
Bing LI
;
Jinqin LIU
;
Kun RU
;
Zhijian XIAO
Author Information
1. Institute of Hematology and Blood Diseases Hospital, Chinese Academe of Medical Sciences, The State Key Laboratory of Experimental Hematology, Tianjin 300020, China
- Publication Type:Journal Article
- Keywords:
Eosinophilia;
Chronic eosinophilic leukemia;
Hyper-eosinophilic syndrome;
Targeted sequencing
- From:
Chinese Journal of Hematology
2018;39(6):501-506
- CountryChina
- Language:Chinese
-
Abstract:
Objective:Analysis of the molecular characteristics of eosinophilia.
Methods:Targeting sequence to 24 patients with chronic eosinophilic leukemia (CEL) with rearrangement of PDGFRA, PDGFRB, or FGFR1 and 62 patients with hyper-eosinophilic syndrome (HES). Mutation annotation and analysis of amino acid mutation using authoritative databases to speculate on possible pathogenic mutation.
Results:Thirty-seven kinds of clonal variant were detected from 17 patients with CEL, no recurrent mutation site and hot spot region were found. No pathogenic mutation was detected in 19 patients with PDGFRA rearrangement, but pathogenic mutations of ASXL1, RUNX1 and NRAS were detected from 2 patients with FGFR1 rearrangement who progressed to acute myeloid leukemia and 1 patient with PDGFRB rearrangement who progressed to T lymphoblastic lymphoma, respectively. One hundred and two kinds of clonal abnormalities were detected in 49 patients with HES. The main hot spot mutation regions included: CEBPA Exon1, TET2 Exon3, ASXL1 Exon12, IDH1 Y208C, and FGFR3 L164V. CRRLF2 P224L and PDGFRB R370C point mutations were detected separately in 2 patients with HES who treated with imatinib monotherapy and achieved hematologic remission.
Conclusion:The pathogenesis of CEL with PDGFRA, PDGFRB or FGFR1 rearrangement is usually single, and the progression of the disease may involve other driver mutation. A variety of genes with hot mutation regions may be involved in the pathogenesis of HES, and some mutation sites are sensitive to tyrosine kinase inhibitors.
